Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.
S
Show more
Pharmaceutical research and development in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, targeted genomic insertion, targeted genomic integration, genetic diseases, gene therapy and cell therapy; Medical laboratory services in the nature of gene editing for developing cells and protein RNA complexes for medical use
Class 42 – Technology & SaaS
Status timeline
- 11 Jan 2022Application filedNew Application Entered
- 20 Jul 2022Assigned to an examining attorneyAssigned To Examiner
- 25 Jul 2022Office action issuedNon-Final Action Written
- 12 Dec 2022Response to office action filedTeas Response To Office Action Received
- 15 Dec 2022Approved for publicationApproved For Pub - Principal Register
- 17 Jan 2023Published for oppositionPublished For Opposition
- 14 Mar 2023Notice of allowance issued — statement of use requiredNoa Mailed - Sou Required From Applicant
- 14 Jul 2023Statement-of-use extension 1 grantedSou Extension 1 Granted
- 13 Mar 2024Statement-of-use extension 2 grantedSou Extension 2 Granted
- 9 Sep 2024Statement-of-use extension 3 grantedSou Extension 3 Granted
- 10 Mar 2025Statement of use filedTeas Statement Of Use Received
- 27 Jun 2025Statement of use acceptedAllowed Principal Register - Sou Accepted
- 16 Jul 2025Statement of use acceptedNotice Of Acceptance Of Statement Of Use E-Mailed
- 22 Jul 2025Registered on the Principal RegisterRegistered-Principal Register
All 35 events
| 2025-07-22 | Registered-Principal Register |
| 2025-07-22 | Notice Of Registration Confirmation Emailed |
| 2025-07-16 | Notice Of Acceptance Of Statement Of Use E-Mailed |
| 2025-06-27 | Allowed Principal Register - Sou Accepted |
| 2025-06-03 | Case Assigned To Intent To Use Paralegal |
| 2025-06-02 | Statement Of Use Processing Complete |
| 2025-03-10 | Teas Statement Of Use Received |
| 2025-03-09 | Use Amendment Filed |
| 2024-09-09 | Sou Teas Extension Received |
| 2024-09-09 | Sou Extension 3 Filed |
| 2024-09-09 | Sou Extension 3 Granted |
| 2024-09-09 | Notice Of Approval Of Extension Request E-Mailed |
| 2024-03-14 | Notice Of Approval Of Extension Request E-Mailed |
| 2024-03-13 | Sou Teas Extension Received |
| 2024-03-13 | Sou Extension 2 Filed |
| 2024-03-13 | Sou Extension 2 Granted |
| 2023-07-18 | Notice Of Approval Of Extension Request E-Mailed |
| 2023-07-14 | Sou Teas Extension Received |
| 2023-07-14 | Sou Extension 1 Filed |
| 2023-07-14 | Sou Extension 1 Granted |
| 2023-03-14 | Noa Mailed - Sou Required From Applicant |
| 2023-01-17 | Published For Opposition |
| 2023-01-17 | Official Gazette Publication Confirmation E-Mailed |
| 2022-12-28 | Notification Of Notice Of Publication E-Mailed |
| 2022-12-15 | Approved For Pub - Principal Register |
| 2022-12-13 | Teas/Email Correspondence Entered |
| 2022-12-12 | Teas Response To Office Action Received |
| 2022-12-12 | Correspondence Received In Law Office |
| 2022-07-25 | Non-Final Action Written |
| 2022-07-25 | Non-Final Action E-Mailed |
| 2022-07-25 | Notification Of Non-Final Action E-Mailed |
| 2022-07-20 | Assigned To Examiner |
| 2022-01-14 | Notice Of Design Search Code E-Mailed |
| 2022-01-13 | New Application Office Supplied Data Entered |
| 2022-01-11 | New Application Entered |
Goods & services by class
Class 42 Technology & SaaS
Pharmaceutical research and development in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, targeted genomic insertion, targeted genomic integration, genetic diseases, gene therapy and cell therapy; Medical laboratory services in the nature of gene editing for developing cells and protein RNA complexes for medical use
First use anywhere 1 Mar 2022 · First use in commerce 1 Mar 2022
Owner details
See the official record for contact details. View official record →
Source & freshness
Source: the official United States trademark register. This record was last updated on 22 Jul 2025; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.